With their novel, insulin‐independent mechanism, sodium‐glucose cotransporter‐2 (SGLT2)
inhibitors are a major turning point in the management of type 2 diabetes mellitus. At …

The age-related decrease in skeletal muscle mass together with the loss of muscle power
and function is defined sarcopenia. Mounting evidence suggests that the prevalence of …

Heart failure (HF) is common and associated with a poor prognosis, despite advances in
treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co …

Background SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2
diabetes and have been shown to reduce body weight. However, it is unclear which body …

Sarcopenia, characterized by loss of skeletal muscle mass, quality, and strength, has
become a common hallmark of ageing and many chronic diseases. Diabetes mellitus …

Weight loss is an important goal in the management of several chronic conditions, including
type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing …

Persons with type 1 or type 2 diabetes have a significantly higher fracture risk than age‐
matched persons without diabetes, attributed to disease‐specific deficits in the …

Background Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular
death and events in patients with diabetes have attracted attention in the cardiology field …

Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an
association with glucose-lowering effect Page 1 2017, 64 (3), 363-367 NONALCOHOLIC …

Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors reduce bodyweight
(BW) by creating a negative energy balance. Previous reports have suggested that this BW …